Hightide Therapeutics Inc
HHKEX:25113.13
HKD
-0.02
(-0.63%)
Hightide Therapeutics Inc
HKEX:2511
(Hong Kong Exchange)
Recent
price
3.13
P/E
ratio
- -
div
yld
- -
ROIC.AI
Capital Structure
CNY
•
in mil. unless spec.Working Capital
CNY
•
in mil. unless spec.Growth Rates
CNY
•
in mil. unless spec.Semi-annual Revenue
CNY
•
in mil. unless spec.Semi-annual Earnings Per Share
CNY
•
in mil. unless spec.Semi-annual Dividends Per Share
CNY
•
in mil. unless spec.- Similar Companies
- Business
- HighTide Therapeutics Inc (2511.HK) is a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic, digestive, and cardiovascular diseases. The company offers a pipeline of investigational drugs including HTD1801 (berberine ursodeoxycholate), an oral first-in-class FXR agonist and TGR5 agonist targeting non-alcoholic steatohepatitis (NASH), primary sclerosing cholangitis (PSC), and ulcerative colitis; HTD4010, a novel oral TGR5 agonist for obesity and metabolic dysfunction-associated steatohepatitis (MASH); and other candidates such as HTD1802 for liver fibrosis and cardiovascular indications, along with earlier-stage programs in metabolic and inflammatory disorders. HighTide operates primarily in the biopharma sector, targeting patients with chronic liver, gastrointestinal, and cardiometabolic conditions through clinical trials and partnerships with global pharmaceutical firms; its geographic footprint spans China, the United States, and select Asia-Pacific regions. Founded in 2015 and headquartered in Shanghai, China, the company maintains subsidiaries and research facilities in San Diego, California, to support its international R&D efforts. HighTide went public on the Hong Kong Stock Exchange in 2024, marking a key capital-raising milestone to advance its late-stage pipeline. In recent developments within the last two years, HighTide reported positive topline results from the Phase 3 GLOBE trial of HTD1801 in PSC in late 2024, paving the way for regulatory submissions; it also initiated the Phase 3 TERN-501 trial for MASH and expanded collaborations with international partners for co-development and commercialization. Additionally, the company secured Series D funding exceeding USD 100 million in 2023 to fuel pipeline progression and announced strategic expansions into obesity treatments with HTD4010 entering clinical stages.